ATHN 4 – Transition of Care for Patients with Venous Thromboembolism (VTE)
With the prevalence of venous thromboembolism (VTE) on the rise, ATHN has launched ATHN 4, a new study aimed at helping to improve the transition of care from an inpatient to an outpatient setting for patients with VTE.
ATHN 4 is taking place at 14 hemophilia treatment centers (HTCs) that are ATHN Affiliates. Along with improving transition of care practices for both adult and pediatric care, the study will also evaluate patient and family understanding and adherence to anticoagulation therapy instructions.
Principal Investigator: Madhvi Rajpurkar, MD, Children’s Hospital of Michigan and Maria T. DeSancho, MD MSc, Weill Cornell Medicine. Sponsor: ATHN. Funding Source: The Joint Commission provides administrative oversight for the program. Pfizer Independent Grants for Learning & Change (IGLC) and Bristol-Myers Squibb Independent Medical Education provides all funding.
- To improve the transition of care from an inpatient to an outpatient environment in patients with VTE specifically looking at delivery and understanding of instructions regarding anticoagulant therapy at the time of discharge.
- To evaluate patient/parent understanding of and adherence to anticoagulation therapy related instructions at approximately 1 week after initial VTE diagnosis and prescribing of anticoagulation with vitamin K antagonists (VKA), direct oral anticoagulants (DOACs) and low molecular weight heparins (LMWH).
- To quantify the number and characteristics of patients prescribed direct oral anticoagulants (DOACs) compared to other anticoagulant therapies as the initial treatment for VTE and compare their impact on TOC.
- To explore the appropriateness of the different antithrombotic regimens as prescribed to manage pediatric, adolescent and adult patients with VTE as they move from an acute to outpatient setting.